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http://dx.doi.org/10.1016/j.gmbhs.2Abstract The aim of this retrospective study was to evaluate the first-line treatment of bev-
acizumab combined with the FOLFIRI (fluorouracil, leucovorin, and irinotecan) regimen, and to
compare the toxicity and efficacy in Taiwanese patients with metastatic colorectal cancer
(mCRC). Fifty-two patients with mCRC receiving bevacizumab combined with FOLFIRI chemo-
therapy in Kaohsiung Medical University Hospital between January 2008 and December 2009
were analyzed retrospectively. The patients were initially treated with bevacizumab [5 mg/
kg; a 120-minute intravenous (IV) infusion] on Day 1, followed by irinotecan (180 mg/m2 as
a 120-minute IV infusion), leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-
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Bevacizumab combined FOLFIRI for metastatic CRC 12346-hour period), repeated every 2 weeks. The characteristics of each patient, the adverse ef-
fects, and responses after chemotherapy were recorded. The objective responses for treat-
ment of patients were evaluated, and the results showed that the overall response rate was
59.6% and the disease control rate was 82.7%. The major Grade 3/4 adverse events encoun-
tered in these patients were asthenia (5.8%), diarrhea (7.7%), nausea (7.7%), vomiting
(3.8%), mucositis (1.9%), hematological toxicity (3.8%), and proteinuria (1.9%). The most com-
mon Grade 3/4 adverse events in our patients were diarrhea (0e15% in Caucasians, 4.2% in
Asian, and 7.7% in the current study), nausea/vomiting (0e6%/0e7% in Caucasians and 7.7%/
3.8% in the current study), neutropenia (9.5e30% in Caucasians and 3.8% in the current study),
hypertension (0e26% in Caucasians and 0% in the current study), and gastrointestinal bleeding
(0e4% in Caucasians and 0% in the current study). The considerable efficacy and safety profile
in this retrospective study showed that bevacizumab combined with FOLFIRI regimen is consis-
tent with the results in prospective randomized clinical trials. The combination of bevacizu-
mab with FOLFIRI regimen for first-line treatment was effective for and well tolerated by
Taiwan mCRC patients.
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Colorectal cancer (CRC) has been the most common malig-
nancy in both genders in Taiwan since 2006. The incidence of
CRC in Taiwan is 41.35/100,000, and 12,488 new cases of CRC
were diagnosed in the country in 2009. Furthermore, more
than 4000 Taiwanese died of CRC in 2009.1 Metastatic dis-
eases were found in 20e25% of patients with initial diagnosis
of CRC and developed in up to 50% of patients.2 Owing to the
limited posttreatment response of 5-fluorouracil (5-FU)
combined with leucovorin (LV) obtained in metastatic colo-
rectal cancer (mCRC) patients, other therapeutic agents
with different mechanisms were considered, such as irino-
tecan (a potent inhibitor of topoisomerase I), which is
involved in the unwinding of DNA during replication.3 The
mechanism of irinotecan and its activity against fluorouracil-
resistant CRC were the rationale for combining this agent
with fluorouracil and leucovorin for the treatment of
mCRC.4e6 Bevacizumab is a humanizedmonoclonal antibody
that inhibits tumor angiogenesis by blocking the vascular
endothelial growth factor and was the first antiangiogenic
agent approved for the treatment of cancer.7
The Bolus, Infusional, or Capecitabine with Camptosar-
Celecoxib (BICC-C) trial has evaluated several different
irinotecan-based regimens in patients with previously un-
treated mCRC including FOLFIRI (fluorouracil, leucovorin,
and irinotecan), mIFL (modified irinotecan and bolus 5-FU/
leucovorin), and capecitabine/irinotecan (CAPIRI).8 The
study randomly assigned 430 patients into three groups,
and those who received FOLFIRI had a better progression-
free survival (PFS) than the patients who received either
mIFL (7.6 vs. 5.9 months, p Z 0.004) or CAPIRI (7.6 vs. 5.8
months, p Z 0.015). Patients who received CAPIRI had
higher rates of Grade 3 nausea, vomiting, diarrhea, dehy-
dration, and handefoot syndrome. When using an
irinotecan-based regimen as the first-line treatment of
mCRC, FOLFIRI regimen is preferred to mIFL regimen.8
A survival benefit was noted in the pivotal study (AVF2107
trial) conducted by Hurwitz and colleagues for the first-line
treatment of mCRC. The patients randomly assigned toreceive IFL and bevacizumab experienced a significantly
better PFS (10.6 months in the group given IFL plus bev-
acizumab, as compared with 6.2 months in the group
given IFL plus placebo; Hazard ratio (HR) for disease
progressionZ 0.54; p< 0.001) and overall survival (OS) (20.3
months in thegroupgiven IFLplusbevacizumab, as compared
with 15.6 months in the group given IFL plus placebo; HR for
death Z 0.66; p < 0.001).9 Bevacizumab was approved for
treatment ofmCRC by the U.S. Food and Drug Administration
in 2004. On the following day, the addition of bevacizumab
for use in the BICC-C trial was requested, and 117 patients
were randomly assigned to receive FOLFIRI plus bevacizumab
or mIFL plus bevacizumab. The result showed that PFS was
not significantly different and that patients had a signifi-
cantly better OS (not yet reached with amedian follow-up of
22.6 vs. 19.2 months; pZ 0.007). In the progression of CRC
treatment, previously untreated mCRC patients undergoing
first-line treatment with FOLFIRI combined with bev-
acizumab had a survival benefit.8 However, these data were
mainly from Caucasians; the therapeutic effect of bev-
acizumab combined with FOLFIRI as a first-line setting in
Taiwan mCRC patients remains unknown.
In this clinical retrospective observational study, using
bevacizumab combined with FOLFIRI as the first-line
treatment for Taiwan mCRC patients, the objective
response and adverse events were explored.
Materials and methods
We conducted a retrospective analysis of patients with
mCRC from January 2008 and December 2009 in Kaohsiung
Medical University Hospital (KMUH). The study was
approved by the ethics committee of KMUH (KMUH-IRB-
20110081). Fifty-two patients were enrolled in this study.
The treatment regimen consisted of bevacizumab [5 mg/
kg; as a 120-minute intravenous (IV) infusion] on Day 1,
followed by irinotecan (180 mg/m2 as a 120-minute IV
infusion), LV (400 mg/m2 IV infusion over 2 hours), and 5-FU
(400 mg/m2 as an IV bolus infusion followed by 2400 mg/m2
IV infusion over a 46-hour period), repeated every 2 weeks.
Table 1 Characteristics of the patients.
N Z 52 (%)
Age, median (y, range) 60 (41e79)
Gender
Male 34 (65.4)
Female 18 (34.6)
Performance status (ECOG)
Before chemotherapy
0 43 (82.7)
1 8 (15.4)
2 1 (1.9)
Primary tumor
Ascending colon 9 (17.3)
Transverse colon 4 (5.8)
Descending colon 7 (13.5)
Sigmoid colon 20 (38.5)
Rectum 13 (25)
Metastases
Synchronous 17 (32.7)
Metachronous 35 (67.3)
Sites of metastases
Liver 26 (50.0)
Lung 8 (15.4)
Peritoneum 2 (3.8)
Distant lymph nodes 1 (1.9)
Bone 1 (1.9)
Adrenal 1 (1.9)
Ovary 1 (1.9)
2 sites 12 (23.1)
CEA (prechemotherapy)
<5 ng/mL 12 (23.1)
5 ng/mL 40 (76.9)
CEAZ carcinoembryonic antigen; ECOGZ Eastern Cooperative
Oncology Group.
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included history and physical examination, routine
biochemistry, blood cell count, serum carcinoembryonic
antigen (CEA) level determination, chest X-ray, and
abdominal computed tomographic (CT) scan. Magnetic
resonance imaging, bone scan, or positron emission to-
mography would be necessary if a specific site of metas-
tases was suspected. Our primary objectives included the
toxicities and the efficacy of bevacizumab combined with
FOLFIRI chemotherapy. The severity of adverse effects
was evaluated according to the National Cancer Institute
Common Toxicity Criteria, version 3.0 (http://ctep.
cancer.gov/reporting/ctc.html; accessed in September
2012).
The courses of chemotherapy were continued in the
presence of an absolute neutrophil count 1500/mL and
platelet count 100,000/mL. For patients with Grade 2 or
more severe hematologic toxicities, treatment was post-
poned for 1 or 2 weeks until recovery. Otherwise, any Grade
3/4 adverse events resulted in an approximately 20% dose
reduction of irinotecan and bolus 5-FU for the subsequent
cycles. The regimen was continued until one of the
following occurred: progressive disease, unacceptable
adverse effects, the patient refused further treatment with
any irinotecan-combination chemotherapy, or the patient
was lost to follow-up.
The patients’ clinical records were retrospectively
reviewed. The characteristics of the patients being recor-
ded include age, gender, Eastern Cooperative Oncology
Group (ECOG) performance status (PS), location of the
primary cancer, involvement of other organs, metastatic
sites, history of operations for CRC, serum CEA level, the
schedule of irinotecan-combination chemotherapy, and the
observed toxicities encountered after the chemotherapy.
We also evaluated the response of each patient after the
chemotherapy.
The response was assessed radiologically with CT
scans, and the best response was recorded. The time for
the first response assessment was usually after the sixth
cycle in patients who received bevacizumab combined
with FOLFIRI chemotherapy. Response reassessments with
CT were typically performed 2e3 months after the first
assessment. Responses were classified according to the
Response Evaluation Criteria in Solid Tumors.10 A com-
plete response was defined as the disappearance of all
target lesions; a partial response was defined as at least a
30% decrease in the sum of the longest diameter of target
lesions, taking as a reference point the baseline sum’s
longest diameter; meanwhile, progressive disease was
defined as at least a 20% increase in the sum of the
longest diameter of target lesions, taking as a reference
the smallest sum of the longest diameters recorded
before the patient started to receive treatment. The
latter could also be indicated if identification of one or
more new lesions was made. A stable disease was defined
as neither having sufficient shrinkage to qualify for a
partial response nor a sufficient increase to qualify for
progressive disease. Moreover, we reported the best
response that was defined as the best one recorded by the
investigators, because the confirmatory image evidence
of response obtained after 4e6 cycles of the chemo-
therapy was not consistently available.Results
A total of 52 patients with mCRC were analyzed retro-
spectively, and their characteristics are summarized in
Table 1. Almost all patients (98.1%) had good initial PS
based on the ECOG PS grading system 0e1 before receiving
bevacizumab combined with FOLFIRI chemotherapy. In
these patients (aged between 41 and 79 years; 34 males and
18 females), 75% of the primary tumors were located in the
colon and 25% in the rectum. Seventeen of the 52 patients
(22.7%) had synchronous metastases at the time of confir-
mation of metastasis. The main sites of metastases (before
chemotherapy) are as follows: liver (26, 50%), lung (8,
15.4%), peritoneum (2, 3.8%), distant lymph nodes (1,
1.9%), bone (1, 1.9%), adrenal (1, 1.9%), and ovary (1,
1.9%). Twelve patients (23.1%) had more than one metas-
tasis site. Moreover, 40 (76.9%) patients were identified as
having abnormal prechemotherapy serum CEA levels (serum
CEA level S5 ng/mL).
The toxicities encountered are listed in Table 2. All pa-
tients were assessable for toxicity. Grade 1e2 allergic re-
actions (transient skin rash and drug fever <38C) were
encountered in only one of the 52 patients. Most of these
Table 2 Toxicities and best objective responses of pa-
tients receiving bevacizumab þ FOLFIRI chemotherapy.
N Z 52 (%)
Toxicities
Allergic reaction
Grade 1e2 1 (1.9)
Asthenia
Grade 1e2 5 (9.6)
Grade 3e4 3 (5.8)
Hypertension
Grade 1e2 5 (9.6)
Diarrhea
Grade 1e2 6 (11.5)
Grade 3e4 4 (7.7)
Constipation
Grade 1e2 3 (5.8)
Nausea
Grade 1e2 5 (9.6)
Grade 3e4 4 (7.7)
Vomiting
Grade 1e2 6 (11.5)
Grade 3e4 2 (3.8)
Mucositis
Grade 1e2 8 (15.4)
Grade 3e4 1 (1.9)
Hematological toxicity
Grade 1e2 9 (17.3)
Grade 3e4 2 (3.8)
Gastrointestinal bleeding
Grade 1e2 1 (1.9)
Hepatic toxicity
Grade 1e2 3 (5.8)
Proteinuria
Grade 1e2 2 (3.8)
Grade 3e4 1 (1.9)
Objective responses
Response 31 (59.6)
Complete response 0
Partial response 31 (59.6)
Nonresponse 21 (40.4)
Stable disease 12 (23.1)
Progressive disease 9 (17.3)
FOLFIRI Z fluorouracil, leucovorin, and irinotecan.
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emetic agents, prokinetics, stool softeners, antidiarrheal
agents, or adequate IV hydration. The main Grade 3/4
adverse events encountered in these patients were
asthenia (5.8%), diarrhea (7.7%), nausea (7.7%), vomiting
(3.8%), mucositis (1.9%), hematological toxicity (neu-
tropenia, 3.8%), and proteinuria (1.9%). Granulocyte colony
stimulating factors were administered to the patients with
severe neutropenia. The objective responses of patients
are also summarized in Table 2. Thirty-one patients were
evaluated for treatment responsed no complete response
was reached, response rate (partial response) was 59.6%,
and the disease control rate was 82.7%.
In the study, we compared Grade 3/4 toxicities of bev-
acizumab combined with FOLFIRI among Caucasians,Asians, and the patients in our study (Table 3).11e18 The
main Grade 3/4 adverse events encountered in these pa-
tients were diarrhea (0e15% in Caucasians, Asian 4.2%, and
7.7% in the current study), nausea/vomiting (0e6%/0e7% in
Caucasians and 7.7%/3.8% in the current study), hemato-
logical toxicity (9.5e30% in Caucasians and 3.8% in the
current study), hypertension (0e26% in Caucasians and 0%
in the current study), and gastrointestinal bleeding (0e4%
in Caucasians and 0% in the current study). Furthermore,
we also compared the overall response rate to bevacizumab
combined with FOLFIRI among Caucasians, Asians, and our
study population (Table 4).11e20 It seemed that the overall
response rate was comparable between Taiwan mCRC pa-
tients (59.6%) and Caucasians (40e53.1%) or other Asian
patients (32.5e53.1%).Discussion
Irinotecan in combination with 5-FU/LV was evaluated as a
first-line therapy for mCRC in two randomized, Phase III
studies. Both trials confirmed that irinotecan plus infused
or bolus 5-FU/LV provided a modest survival benefit without
compromising the patients’ quality of life.5,6 Combination
therapy with irinotecan-base chemotherapy represents a
standard in first-line treatment of mCRC. The BICC-C trail
showed no significant difference in terms of OS and overall
response rates among FOLFIRI, mIFL, and CapeIRI groups,
but indicated a better PFS in the FOLFIRI group for previ-
ously untreated mCRC. FOLFIRI was associated with the
lowest rates of diarrhea and febrile neutropenia.8
In a Phase III trial, bevacizumab in combination with IFL
increased the survival rate compared with IFL alone as first-
line treatment for mCRC.9 Hurwitz et al9 described the
efficacy and safety results of the patients who received
bevacizumab combined with 5-FU/LV and compared them
with the results of concurrently enrolled patients who
received IFL. The median OS was 20.3 and 15.6 months with
bevacizumab/IFL and IFL alone, respectively. Meanwhile,
the PFS was 10.6 and 6.2 months, respectively. The overall
response rates were 45% and 35%, respectively.8 The dose
of irinotecan was repeated weekly for 4 weeks, which was
not convenient as the FOLFIRI regimen is given biweekly.
The Period 2 study of the BICC-C trial compared the results
of using bevacizumab with FOLFIRI or mIFL. The results
showed significantly greater OS in bevacizumab plus FOL-
FIRI, but no difference in terms of PFS and overall response
rates in both groups.8 Bevacizumab plus FOLFIRI had higher
rates of nausea, vomiting, dehydration, and febrile neu-
trpopenia than bevacizumab plus mIFL, but it was well
tolerated.
The present study has demonstrated a favorable
response rate and relatively low toxicities of combining
bevacizumab and FOLFIRI as the first-line setting of therapy
for mCRC patients in Taiwan. Additionally, we compared
the differences among Caucasians, other Asians, and our
patients in terms of toxicity effects. Except for similar
diarrhea and nausea/vomiting rates, we also found that
most toxicity effects were less severe in Taiwan mCRC pa-
tients than in Caucasian patients when bevacizumab com-
bined with FOLFIRI was administered. Moreover, it was
shown that the overall response rate was comparable
Table 3 Comparison of common Grade III/IV toxicities of bevacizumab þ FOLFIRI among Caucasians, Asians, and our study
population.
Caucasians Asians Our Study
Diarrhea 15% (Rosati et al11) 4.2% (Nishi et al18) 7.7%
15% (Stintzing et al12)
12% (Sobrero et al13)
9.2% (Souglakos et al14)
8.5% (Lo´pez et al15)
0% (Ocvirk et al16)
Nausea/vomiting 6%/7% (Sobero et al13) 7.7%/3.8%
4% (Rosati et al11)
3.2% (Souglakos et al14)
2% (Stintzing et al12)
0% (Ocvirk et al16)
0% (Lo´pez et al15)
Hematological toxicity 30% (Rosati et al11) 3.8 % (neutropenia)
29% (Sobrero et al13)
24.5% (Souglakos et al14)
23% (Ocvirk et al16)
17% (Stintzing et al12)
9.5% (Lo´pez et al15)
Hypertension 26% (Rosati et al11) 0 %
22% (Stintzing et al12)
5% (Van Cutsem et al17)
5% (Sobrero et al13)
5% (Ocvirk et al16)
3.8% (Souglakos et al14)
0% (Lo´pez et al15)
Gastrointestinal bleeding 4% (Sobrero et al13) 0 %
3% (Van Cutsem et al17)
2% (Stintzing et al12)
2% (Rosati et al11)
0% (Souglakos et al14)
0% (Ocvirk et al16)
FOLFIRI Z fluorouracil, leucovorin, and irinotecan; NCI-CTI, National Cancer Institute Common Toxicity Criteria.
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Asian patients.
Our previous study evaluated the two different regimens
of irinotecan-base chemotherapy for treatment of Taiwan
mCRC patients.21 The results showed no significant differ-
ence in overall responses and PFS in both IFL and FOLFIRI
groups, but there were slight increments in neutropenia,
leucopenia, diarrhea, and nausea/vomiting in the FOLFIRITable 4 Comparison of overall response rate of bevacizumab
study population.
Caucasians
Overall response rate 53.1% (Sobero et al13)
50.5% (Lo´pez et al15)
49.8% (Rosati et al11)
48% (Stintzing et al12)
45.5% (Souglako et al14)
40% (Ocvirk et al16)
Overall response rate Z complete response rate þ partial response rgroup compared with the IFL group.21 The regimen of
FOLFIRI is repeated every 2 weeks, whereas IFL is used
weekly; hence, it is more acceptable to use FOLFIRI for
patients in Taiwan. However, a prospective, randomized
trial to evaluate the toxicities and safety of bevacizumab
combined with FOLFIRI or IFL regimen is needed.
In conclusion, the combinations of bevacizumab with
FOLFIRI for first-line treatment were active and well-þ FOLFIRI chemotherapy among Caucasians, Asians, and our
Asians Our study
53.1% (Nishi et al18) 59.6%
34.1% (Yildiz et al19)
32.5% (Odabas et al20)
ate.
Bevacizumab combined FOLFIRI for metastatic CRC 127tolerated treatments among mCRC patients in Taiwan. For
the majority of patients, toxic effects encountered after
chemotherapy were reversible and manageable. After
analyzing their efficacy in Caucasians and other Asian pa-
tients, we found a comparable overall response rate and
disease control rate in mCRC patients who received bev-
acizumab combined with FOLFIRI chemotherapy as the
first-line setting in Taiwan. In consideration of the efficacy
and safety profiles, we suggest that bevacizumab combined
with FOLFIRI regimen could be considered as the effective
frontline regimen of irinotecan-based chemotherapy for
Taiwanese patients with mCRC.
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